USP47 and chronic myelogenous leukemia, BCR-ABL1 positive: Targeting USP47 is a promising strategy to overcome tyrosine kinase inhibitor resistance and eradicate leukemia stem/progenitor cells in chronic myelogenous leukemia (41).